StockNews.AI

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

StockNews.AI • 1 minute

VRTXSNYPFE
High Materiality8/10

Information

SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today an...

Original source

AI Summary

Crinetics Pharmaceuticals granted stock options and RSUs to 10 new non-executive employees as incentives to join the company, in compliance with Nasdaq rules. This move reflects the company's focus on building a strong workforce as it advances multiple therapeutic candidates, potentially enhancing future growth and revenue streams.

Sentiment Rationale

Increased employee incentives can lead to improved operational performance and product development, similar to past instances where key hires and talent retentions led to company growth.

Trading Thesis

Invest in CRNX for potential growth due to expanding employee incentives and pipeline advancements over the next 6-12 months.

Market-Moving

  • Stock options and RSUs might boost morale and retention of new talent.
  • Compliance with Nasdaq rules solidifies governance standing, potentially attracting investors.
  • Pipelines advancing with innovative therapies could drive share price appreciation.
  • The recent stock option pricing reflects market valuation stability, serving as a potential support level.

Key Facts

  • Crinetics granted stock options for 37,575 shares to new employees.
  • 25,525 RSUs awarded to 10 non-executive employees.
  • Awards incentivize recruitment under Nasdaq Rule 5635(c)(4).
  • Stock options priced at $53.25, equal to January 9 closing price.
  • Crinetics focuses on endocrine diseases and G-protein coupled receptors.

Companies Mentioned

  • Crinetics Pharmaceuticals, Inc. (CRNX): Strategically expanding talent base to enhance competitive positioning.

Corporate Developments

This news fits the 'Corporate Developments' category as it details employee incentivization strategies, essential for talent acquisition and retention, thus impacting long-term growth potential.

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Rule 5635(c)(4)

SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) has revealed that its Compensation Committee granted significant stock options and restricted stock unit (RSU) awards to new employees on January 10, 2026. This strategic move is part of the company's efforts to entice talent as outlined in the Nasdaq Listing Rule 5635(c)(4).

Details of the Inducement Grants

The Compensation Committee approved the following:

  • Stock Options: Non-qualified stock option awards to purchase a total of 37,575 shares of common stock.
  • Restricted Stock Units: An aggregate of 25,525 RSUs awarded to 10 new non-executive employees.

These grants were made under the 2021 Employment Inducement Incentive Award Plan, aimed at attracting individuals who were not prior employees of Crinetics or who had recently ended their employment with the company.

Vesting Schedule and Terms

The stock options have an exercise price set at $53.25 per share, matching the closing price of Crinetics’ stock on the Nasdaq Global Select Market as of January 9, 2026. The vesting structure for the stock options is as follows:

  • 25% of the shares will vest on the one-year anniversary of the vesting commencement date.
  • The remaining shares will vest in equal monthly installments over the next three years, contingent on continued employment.

Similarly, the RSUs will vest over four years in equal annual installments commencing on the one-year anniversary of the applicable vesting commencement date, also subject to continued employment with Crinetics.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a pioneering global pharmaceutical firm focused on the treatment of endocrine diseases and related tumors. The company excels in the discovery, development, and commercialization of novel therapies that target G-protein coupled receptors (GPCRs) with uniquely tailored pharmacological properties.

The firm’s flagship product, PALSONIFY™ (paltusotine), represents the first FDA-approved once-daily oral therapy for adults with acromegaly who have not adequately responded to surgery or for whom surgery is not a feasible option. Additionally, paltusotine is in clinical trials for managing carcinoid syndrome linked to neuroendocrine tumors.

Crinetics boasts a robust pipeline with over 10 disclosed programs focusing on various endocrine disorders, including:

  • Investigational candidate atumelnant for congenital adrenal hyperplasia.
  • ACTH-dependent Cushing’s syndrome.
  • Neuroendocrine tumors, hyperparathyroidism, and diabetes.

Investor and Media Contacts

For further inquiries, investors may contact:

For media inquiries, please reach out to:

Related News